- Krystal Biotech reçoit un avis positif de la part du Comité pédiatrique de l'EMA pour son plan d'investigation pédiatrique sur B-VEC pour le traitement de l'épidermolyse bulleuse dystrophique
- Krystal Biotech erhält positive Stellungnahme des Pädiatrieausschusses der EMA hinsichtlich des pädiatrischen Prüfkonzepts für B-VEC bei der Behandlung von dystropher Epidermolysis bullosa
- Krystal Biotech Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for B-VEC for the treatment of Dystrophic Epidermolysis Bullosa
Key statistics
On Wednesday, Krystal Biotech Inc (KRYS:NMQ) closed at 117.85, -4.84% below its 52-week high of 123.84, set on May 23, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 115.99 |
---|---|
High | 118.81 |
Low | 115.52 |
Bid | 111.75 |
Offer | 187.80 |
Previous close | 117.85 |
Average volume | 548.96k |
---|---|
Shares outstanding | 27.53m |
Free float | 20.57m |
P/E (TTM) | -- |
Market cap | 3.24bn USD |
EPS (TTM) | -5.28 USD |
Data delayed at least 15 minutes, as of May 31 2023 21:00 BST.
More ▼